An interventional study of Beechband in Parkinson Disease (PD), sponsored by University of Exeter. Active, not recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by University of Exeter · Not applicable, Interventional, and Treatment
Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 105th largest by planned enrollment of the 183 interventional ones, is one of 11 that started in 2026, is one of 58 with no phase, reaches primary completion later than 29 of the 65 other live ones, and was the 244th registered.
4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 60 is above the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now, in 12 countries. Each count lists the studies.
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →246 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 11 started in 2026.
Median enrollment 80 across the 183 interventional studies, 100 across the 62 observational. Of the 152 that completed or were terminated, 45 (30%) have results posted.
122 of 246 have an industry lead sponsor. The 10 most frequent:
University of Exeter is the lead sponsor of 140 studies on the registry; 25 are open to participants now.
University of Exeter has 9 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
16 of the studies in Parkinson Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821151University of ExeterThe Effect of Beechband on Parkinson's Symptoms | 2026-11-10 |
| NCT05986643University of LeicesterBrain Training to Improve Balance in Parkinson's Disease | 2026-12 |
| NCT05635409Region SkaneA Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease | 2027-01 |
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
| NCT07882108Cambridge University Hospitals NHS Foundation TrustGinger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease | 2027-03-01 |
Among the 246 studies in Parkinson Disease with a site in United Kingdom, from their registry updates:
Parkinson's disease can affect movement, balance, and everyday activities. The Beechband is a wrist-worn device that provides intermittent vibrations. Some people have reported improvements in symptoms while wearing the device, but there is currently little scientific evidence to support these reports.
This pilot study will explore whether movement symptoms and participants' perceptions of their symptoms change after wearing the Beechband for 6 or 12 weeks. Approximately 60 people with Parkinson's disease will be randomly assigned to one of two groups. One group will wear the Beechband for 12 weeks. The other group will continue their usual activities without the Beechband for the first 6 weeks and will then wear it for the following 6 weeks. Participants will be asked to wear the device for approximately 6 hours each day during their assigned wearing period.
Assessments will be conducted remotely by video call at the beginning of the study and after 6 and 12 weeks. They will include measures of movement and balance, a timed walking task, and questionnaires about symptoms and everyday experiences. Device use and any unwanted or unexpected effects will also be recorded.
The study is intended to estimate the size of any possible changes and assess the feasibility of a future larger clinical trial. It is not designed to provide definitive evidence that the Beechband is effective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants wear the Beechband for approximately 6 hours per day throughout the 12-week study period.
Device: Beechband
Participants continue their usual activities without wearing the Beechband during the first 6 weeks. They then wear the Beechband for approximately 6 hours per day during Weeks 6-12.
Device: Beechband
The Beechband is a wrist-worn device that delivers intermittent vibrotactile stimulation. Participants are instructed to wear the device for approximately 6 hours per day during their assigned intervention period, following the manufacturer's guidance. Arm 1: Participants in the IMMEDIATE start arm wear the device for 12 weeks. Arm 2: Participants in the DELAYED start arm wear the device during Weeks 6-12. During selected remote assessments following a Beechband wearing period, movement measures are completed with the device switched on and switched off.
Modified Unified Parkinson's Disease Rating Scale Motor Score (Modified UPDRS)
Motor symptoms are assessed remotely using the Unified Parkinson's Disease Rating Scale. Items that cannot be assessed reliably by video, including rigidity and postural instability, are omitted. Retained items are scored and summed, with higher scores indicating more severe motor symptoms. Assessments following a Beechband-wearing period also include measurements with the device switched on and switched off.
Time frame: Baseline, Week 6, and Week 12
Timed Up and Go Test Completion Time
Time in seconds required to stand from a chair, walk 3 metres, turn, return, and sit down. A shorter time indicates better functional mobility.
Time frame: Baseline, Week 6, and Week 12
Falls Efficacy Scale - International (FES-I)
Self-reported concern about falling during everyday activities. Higher scores indicate greater concern about falling.
Time frame: Baseline, Week 6, and Week 12
Visual Sensitivity Scale (VSS)
Self-reported symptoms associated with visually complex or moving environments
Time frame: Baseline, Week 6, and Week 12
Gait Specific Attentional Profile (G-SAP)
Self-reported attention directed toward walking and movement.
Time frame: Baseline, Week 6, and Week 12
Generalised Anxiety Scale (GAD-7)
Seven-item measure of anxiety symptoms, ranging from 0 to 21; higher scores indicate greater anxiety.
Time frame: Baseline, Week 6, and Week 12
Montreal Cognitive Assessment Total Score (MOCA)
Measure of cognitive function completed remotely, including drawing tasks shown to the researcher by video.
Time frame: Baseline
Rapid Assessment of Physical Activity Score (RAPA)
Self-reported level of physical activity during the preceding two weeks.
Time frame: Every 2 weeks through Week 12
Self Reported Beechband Use
Average number of hours per day and frequency of Beechband use during the preceding two weeks.
Time frame: Every 2 weeks during the assigned wearing period, through Week 12
Participant Withdrawal Rate
Number and percentage of enrolled participants who withdraw before completing the Week 12 assessment.
Time frame: Through Week 12
Adverse Events
Number and type of unwanted or unexpected health events reported during the study, including discomfort and dizziness.
Time frame: Every 2 weeks and through Week 12
Plan to share: Yes — Fully anonymised individual participant data supporting the published study findings will be shared through the Open Science Framework. Shared data may include motor-assessment scores, functional mobility outcomes, physical activity measures, and information about device use and adverse events. Names, contact information, dates of birth, postal addresses, linking information, questionnaire responsese and video recordings will not be shared. Supporting materials, including a data dictionary, study protocol, and relevant analysis information, will be provided where possible. Data will be made available following completion of the study and publication of the main findings, anticipated by December 2027. The repository record and web address will be added when available. Access will be open, subject to the repository's terms and the reuse licence applied to the dataset.
Supporting information: Study protocol, Analytic code
Time frame: The anonymised individual participant data and supporting information will be made available from December 2027, following completion of the study and preparation of the main study findings. The materials will remain available through the repository without a planned end date.
Access criteria: Fully anonymised individual participant data and supporting materials will be made openly available through Open Research Exeter (ORE). Researchers and members of the public will be able to access these materials without submitting an application or obtaining approval. Access and reuse will be governed by the repository's terms and the licence assigned to the dataset. Only data from participants who have consented to data sharing will be included. Identifiable information, participant-code linking files, and video recordings will not be shared.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.
Of 1,291 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 6 months is below that.
Counting every sponsor, half of 1,367 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.